Correction: Ficany et al. Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. <i>J. Clin. Med.</i> 2025, <i>14</i>, 7724.

The sentence “Patients treated with bevacizumab showed non-statistically significant improvements in hematologic parameters and epistaxis” has been replaced by “Because the trial was underpowered, the primary outcome—the comparison of success rates defined as a ≥50% reduction in red blood cell (RBC) transfusions—did not reach statistical significance (63.6% vs. 33.3%).

also in 111,027 other papers